Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with investments in three European biotechs. Sanifit led the way, raising a €55.2 million ($62.9 million) series D ...

HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months ...

Halozyme, a biotech firm whose drug delivery technology is a key component of biologic medicines marketed by several big pharma partners, aims to expand its offerings to these customers through the ...

Halozyme has withdrawn its offer to buy biopharmaceutical services firm Evotec for €2 billion, a move that comes after repeated requests to meet with the company to discuss a deal were all turned down ...

HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim ...

Germany-based CRO Evotec is buying U.S. counterpart Aptuit in a $300 million deal, broadening expertise in the respiratory and fibrosis therapeutic areas, while filling the service gap between ...

Evotec remains a speculative 'Buy' with a €20/share price target, offering high long-term potential but requiring patience for upside realization. The company is refocusing on core strengths, ...

On Thursday, Evotec SE (NASDAQ:EVO) entered a technology development partnership with Novo Nordisk A/S (NYSE:NVO) in cell therapy. Evotec and Novo Nordisk have significant expertise and a strategic ...

Evotec has inked a deal to sell its biologics manufacturing facility in Toulouse, France, to generics giant Sandoz for around $300 million. The transaction advances Evotec's plan to forge an ...